Status:
COMPLETED
A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will provide vaniprevir 600 mg or 300 mg twice daily in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) to participants with chronic hepatitis C virus (HCV) infection wh...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Participant has participated in a prior vaniprevir clinical trial
- Participant agrees to use acceptable birth control method during treatment
- Exclusion criteria:
- More than one year has passed since the participant was determined to be eligible for enrollment in protocol 028
- Participant discontinued vaniprevir and/or peg-IFN and/or RBV in the prior study due to a safety or tolerability issue
- Participant received any investigational therapy for HCV after participating in the prior study
Exclusion
Key Trial Info
Start Date :
October 23 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 29 2013
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00943761
Start Date
October 23 2009
End Date
May 29 2013
Last Update
February 8 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.